Hepion Pharmaceuticals, Inc. reports material agreement in SEC 8-K

Hepion Pharmaceuticals, Inc. filed an 8-K covering a material definitive agreement, an acquisition or disposition of assets, an unregistered sale of equity securities, and director or executive-officer changes. Nelo verified the filing topics against the primary SEC document. This is a company disclosure filed with the SEC, not an SEC enforcement action.